The value of CAR T-cell therapy in refractory or relapsed diffuse large B cell lymphoma (RR DLBCL) has been further boosted by a study showing the salvage therapy also leads to better physical and social function in addition to its impressive survival outcomes in patients with advanced disease. In a post hoc analysis of patient-reported ...
CAR T-cell therapy restores quality of life to normal: study
By Sunalie Silva
17 Mar 2020